Everything below concerns AOD9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-05. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
== Downstream processing == After separation, an additional separation method may then be used, such as isoelectric focusing or SDS-PAGE. The gel will then be physically cut, and the protein complexes extracted from each portion separately. Each extract may then be analysed, such as by peptide mass fingerprinting or de novo peptide sequencing after in-gel digestion. This can provide a great deal of information about the identities of the proteins in a complex.
== Polymerization == Polypropylene glycol is produced by ring-opening polymerization of propylene oxide. The initiator is an alcohol and the catalyst a base, usually potassium hydroxide. When the initiator is ethylene glycol or water the polymer is linear. With a multifunctional initiator like glycerine, pentaerythritol or sorbitol the polymer branches out.
== Substrate specificity == The phytaspase displays a strict substrate specificity, which resembles that of the animal caspase-3. It recognizes a tetrapetide motive within a target protein and introduces a peptide bond break following an aspartate residue, which is crucial for the hydrolysis. Theoretical speculations, based on a 3D model predictions have been made, pointing to the histidine 331 of the phytaspase peptide chain, that might interact with the Asp in the target peptide and thereby guide the recognition.
Sources: en.wikipedia.org
=== Part two === The next evening, James, Cordelia and Matthew accompany Anna to Hell Ruelle, where Hypatia is hosting a party. Lucie, Christopher and Thomas spy on the Enclave meeting and find out that Oliver, Barbara's ex-fiancee had died as well, seemingly due to the fact that Barbara had scratched him before her death. This shocked the entire Enclave as demon poison had never been contagious before, and London is placed immediately under quarantine. In Hell Ruelle, Anna seduces Hypatia and Cordelia performs in front of the gathering. James and Matthew are impressed, however they notice Charles entering the club. Matthew pushes the couple away and they hide in The Whispering Room, where James and Cordelia kiss passionately. The next morning the Merry Thieves, Lucie, and Cordelia take advantage of the fact that Will and Tessa are gone for day-patrols, an added precaution by the Clave, and empty the Pyxis by letting out a Palpis demon named Agliarept, so that they may use it to trap the Mandikhor. They kill the demon before he could sway them. Since they performed it in the Sanctuary, Magnus walks in on them inquiring about their actions. They explain to him, their plans of ridding the shadow world of the demon and Cordelia implores Magnus to help them by casting an illusion over Tower Bridge, to protect and distract the mundanes. Magnus agrees. While they are going towards Tower Bridge, Magnus disproves James' theory of his grandfather being Belphegor.
=== SARS-CoV-2 (COVID-19) === In the beginning of the COVID-19 pandemic, then-US President Donald Trump delivered a very dangerous message to the public on the use of disinfectants, which was immediately rejected and refuted by health professionals. In essence, and as mentioned above, virucides are usually toxic depending on concentrations, mixture, etc., and can be deadly not just to viruses, but also if inside a human or animal body or on surface of body. With regards to the COVID-19 pandemic, some of the mentioned agents are still under research about their microbicidal activity and effectivity against SARS-CoV-2, e.g., on surfaces, as mouth-washes, hand-washing, etc. A mixture of 62–71% ethanol, 0.5% hydrogen peroxide or 0.1% sodium hypochlorite is found to be able to deactivate the novel Coronavirus on surfaces within 1 minute. A 2020 systematic review on hydrogen peroxide (H2O2) mouth-washes concludes, that they don't have an effect on virucidal activity, recommending that "dental care protocols during the COVID-19 pandemic should be revised." Additional research with relation to the Coronavirus virucidal efficacy is on-going. Various information and overview of light-based strategies (UV-C and other types of light sources; see also Ultraviolet germicidal irradiation) to combat the COVID-19 pandemic are available.
=== Glucagon Secretion and Control of Gluconeogenesis === Glucagon functions to signal the liver to begin gluconeogenesis which increases glucose levels in the blood. Glucagon will bind to the glucagon receptors on the plasma membranes of hepatocytes (liver cells). This ligand binding causes the activation of adenylate cyclase, which causes the creation of cyclic AMP (cAMP). As the intracellular concentration of cAMP rises, protein kinase A (PKA) is activated and phosphorylates the transcription factor cAMP Response Element Binding (CREB) protein. CREB then induces transcription of glucose-6-phosphatase and phosphoenolpyruvate carboxylase (PEPCK). These enzymes increase gluconeogenic activity. PKA also phosphorylates phospho-fructokinase 2 (PFK2)/fructose 2,6-biphsophatase (FBPase2), inhibiting PFK2 and activating FBPase2. This inhibition decreases intracellular levels of fructose 2,6-biphosphate and increases intracellular levels of fructose 6-phosphate which decreases glycolytic activity and increases gluconeogenic activity. PKA also phosphorylates pyruvate kinase which causes an increase in intracellular levels of fructose 1,6-biphosphate and decreases intracellular levels of pyruvate, further decreasing glycolytic activity. The most important action of PKA in regulating gluconeogenesis is the phosphorylation of phosphorylase kinase which acts to initiate the glycogenolysis reaction, which is the conversion of glycogen to glucose, by converting glycogen to glucose 1-phosphate. Glucagon is a peptide hormone derived from the proglucagon precursor.
Sources: en.wikipedia.org
== Firazyr (icatibant) == Jerini's lead compound Firazyr (icatibant), is an inhibitor of the action of the hormone bradykinin on its B2 receptor. This compound was in-licensed from Aventis in 2001. It has been approved for hereditary angioedema in all member states of the European Union in July 2008. The drug was granted FDA approval on August 25, 2011.
=== Male breasts === Both females and males develop breasts from the same embryological tissues. Anatomically, male breasts do not normally contain lobules and acini that are present in females. In rare instances, it is possible for very few lobules to be present; this makes it possible for some men to develop lobular carcinoma of the breast. Normally, males produce lower levels of estrogens and higher levels of androgens, namely testosterone, which suppress the effects of estrogens in developing excessive breast tissue. In boys and men, abnormal breast development is manifested as gynecomastia, the consequence of a biochemical imbalance between the normal levels of estrogen and testosterone in the male body. Around 70% of boys temporarily develop breast tissue during adolescence. The condition usually resolves by itself within two years. When male lactation occurs, it is considered a symptom of a disorder of the pituitary gland.
=== Impregnation === Due to its low viscosity while retaining solvent capacities, supercritical carbon dioxide is also used for impregnation of different raw materials. The biggest industrial application in this field is impregnation of wood with biocides. The big advantage is, that the CO2 can penetrate the complete structure of the board, carrying the active ingredient and therefore fully impregnating it.
In September 1984, during a briefing session chaired by He Zai, the secretary-general of the CCP Central Organization Department, Xi's strategic vision and comprehensive understanding of Zhengding County's development were highlighted. He Zai, along with Wei Jianxing, deputy head of the CCP Central Organization Department, communicated these findings to Hu Yaobang, describing Xi as a leader with a strategic outlook and a strong alliance ideology between workers and peasants. In 1985, Xi participated in a study tour on corn processing and traveled to Iowa, the United States, to study agricultural production and corn processing technology. During his visit to the U.S., the CCP Central Organization Department decided to transfer him to Xiamen as a member of the Standing Committee of the CCP Xiamen Municipal Committee and as vice mayor.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.